IKB alpha degradation Antibody Panel (IKK alpha, IKK beta, IKB alpha) Reference: ARG30255 IKB alpha degradation antibody; IKK alpha antibody; IKK beta antibody; IKB alpha antibody
Voxalatamab Reference: HY-P99517 Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody that binds PSMA and CD3 and has anti-cancer activity for use in prostate cancer research.
Loading Controls for Whole Cell Lysate Antibody Panel Reference: ARG30258 Loading Controls for Whole Cell Lysate antibody; GAPDH antibody; beta Actin antibody; alpha Tubulin antibody; Vinculin antibody
Lecanemab Reference: HY-P99689 Lecanemab (BAN-2401) is an IgG1 anti-soluble aggregated amyloid beta (Aβ) monoclonal antibody. Lecanemab shows activity across oligomers, protofibrils and insoluble fibrils. Lecanemab can be used for the research of Alzheimer's Disease.
Loading Controls for Cytoplasmic / Nuclear Fractions Antibody Panel Reference: ARG30259 Loading Controls for Cytoplasmic / Nuclear Fractions antibody; GAPDH antibody; COX4 antibody; Histone H3 antibody
Nurulimab Reference: HY-P99760 Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) humanized monoclonal antibody. Nurulimab can be can be used in research of melanoma.
Kininogen ELISA Antibody Duo Reference: ARG30260 This gene uses alternative splicing to generate two different proteins- high molecular weight kininogen (HMWK) and low molecular weight kininogen (LMWK). HMWK is essential for blood coagulation and assembly of the kallikrein-kinin system. Also, bradykinin, a peptide causing numerous physiological effects, is released from HMWK. Bradykinin also functions as an antimicrobial peptide with antibacterial and antifungal activity. In contrast to HMWK, LMWK is not involved in blood coagulation. Three transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2014]
Gefurulimab Reference: HY-P99638 Gefurulimab (ALXN-1720) is a human-derived bispecific antibody against complement C5 and albumin that binds C5 and blocks its activation.
Toralizumab Reference: HY-P99325 Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab, a immunosuppressive agent, has the potential for active systemic lupus erythematosus (SLE) research.
Obrindatamab Reference: HY-P99762 Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer.